Neurocrine Biosciences logo

Neurocrine Biosciences Income Statement

Revenue, expenses, and profitability over time

Neurocrine Biosciences generated $3.1B in trailing twelve-month revenue, up 0.3% year-over-year. Net income was $668.6M with a 21.55% net margin. Gross margin stands at 98.17% and operating margin at 25.43%. Diluted EPS is $6.49, which grew 1.2% year-over-year. Based on the Q1 2026 filing.

Latest FilingQ1 2026
Report Date2026-05-05
Market Cap$15.7B
P/E Ratio23.52
ROE22.5%

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Capital Expenditures$7.3M$10.7M$12.5M$13.2M$0.0$9.1M
Change in Accounts Receivable$0.0$36.9M$79.7M$132.3M$81.4M
OCI - Available-for-sale securities, net of tax-$5.1M$1.7M$2.7M-$900.0K$0.0-$12.7M
OCI Net Unrealized Gain (Loss) on Securities-$5.1M$1.7M$2.7M-$900.0K$0.0-$12.7M
OCI Available for Sale Securities Adjustment-$5.1M$1.7M$2.7M-$900.0K$0.0-$12.7M
Unrealized Gains on Available-for-Sale Securities-$5.1M$1.7M$2.7M-$900.0K$0.0-$12.7M
OCI - Available-for-Sale Securities, Net of Tax-$5.1M$1.7M$2.7M-$900.0K$0.0-$12.7M
Comprehensive Income (Loss), Net of Tax, Attributable to Parent$94.4M$11.1M$111.0M$210.2M$153.6M$185.2M
Depreciation$6.2M$6.6M$6.3M$6.7M$6.4M$7.2M
Gain on sale of business and assets$0.0$28.6M
Income taxes paid$73.0M$600.0K$71.9M$1.1M$7.8M$300.0K
Accounts payable and other current liabilities$77.3M-$3.0M$30.9M$55.8M$76.5M-$14.3M
Increase (Decrease) in Accounts Receivable$0.0$36.9M$79.7M$132.3M$81.4M
Increase (Decrease) in Inventories$11.6M$1.7M-$2.1M$12.3M$3.4M-$4.3M
Unrealized gains (losses) on available-for-sale securities-$5.1M$1.7M$2.7M-$900.0K$0.0-$12.7M
Payments to Acquire Property, Plant, and Equipment$7.3M$10.7M$12.5M$13.2M$0.0$9.1M
Proceeds from Issuance of Common Stock$10.0M$32.1M$14.4M$45.6M$37.3M$23.6M
Research and development expense$185.6M$263.2M$244.3M$250.0M$258.2M$296.2M
Revenue From Contract With Customer Excluding Assessed Tax$627.7M$572.6M$687.5M$794.9M$805.5M$814.5M
Stock-based compensation$66.4M$52.8M$52.8M$53.7M$58.6M$57.2M
Other Comprehensive Income (Loss)-$5.1M$1.7M$2.7M-$900.0K$0.0-$12.7M
OCI Available for Sale Securities Adjustment, Net of Tax-$5.1M$1.7M$2.7M-$900.0K$0.0-$12.7M
OCI Unrealized Gain (Loss) on Securities, Pre-tax-$5.1M$1.7M$2.7M-$900.0K$0.0-$12.7M

Tax

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Income tax expense$59.5M$6.8M$52.0M$82.3M$85.7M$48.9M

Net Income

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Net income$103.1M$7.9M$107.5M$209.5M$153.7M$197.9M

Revenue

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Total revenue$627.7M$572.6M$687.5M$794.9M$805.5M$814.5M